A share price of Jaguar Health Inc [JAGX] is currently trading at $1.28, up 11.30%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The JAGX shares have gain 24.27% over the last week, with a monthly amount glided 30.63%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Jaguar Health Inc [NASDAQ: JAGX] stock has seen the most recent analyst activity on July 07, 2021, when Cantor Fitzgerald initiated its Overweight rating and assigned the stock a price target of $5. Previously, Rodman & Renshaw started tracking the stock with Buy rating on July 11, 2017, and set its price target to $2.
Jaguar Health Inc experienced fluctuations in its stock price throughout the past year between $0.84 and $21.60. Jaguar Health Inc [NASDAQ: JAGX] shares were valued at $1.28 at the most recent close of the market.
Analyzing the JAGX fundamentals
Trailing Twelve Months sales for Jaguar Health Inc [NASDAQ:JAGX] were 10.48M which represents 10.49% growth. Gross Profit Margin for this corporation currently stands at 0.69% with Operating Profit Margin at -2.85%, Pretax Profit Margin comes in at -3.66%, and Net Profit Margin reading is -3.6%. To continue investigating profitability, this company’s Return on Assets is posted at -0.65, Equity is -2.88 and Total Capital is -0.77. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of2.44.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.1767 points at the first support level, and at 1.0733 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.3567, and for the 2nd resistance point, it is at 1.4333.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Jaguar Health Inc [NASDAQ:JAGX] is 1.84. In addition, the Quick Ratio stands at 1.36 and the Cash Ratio stands at 0.67. Considering the valuation of this stock, the price to sales ratio is 1.52, the price to book ratio is 0.98.
